Turn Therapeutics Inc.
NASDAQ:TTRXBiotechnology
-$0.17 today
- Market cap
- $271.79M
- Beta
- 2.77
- P/E (TTM)
- -45.0
- EPS (TTM)
- -$0.13
Volume 0.05M
Average 0.04M
TTRX Net Debt
Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.
Turn Therapeutics Inc.NASDAQ: TTRX
Net Debt · Q1 FY2026 · quarter ended Mar 2026
Net debt of -$5.21M in Q1 FY2026
Q1 FY2026 net debt was -$5.21M.
Context
- Net debt amounted to 28.0% of total assets at the end of Q1 FY2026.
- Net debt grew in size in 1 of the last 2 fiscal years.
- FY2025 was the largest annual figure in the 3 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Debt history
USD · from the balance sheet
- Latest · FY2025
- (5M) USD
- Year-over-year change
- -564.7%
| Period | Period end | Net Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (5M) | -564.7% |
| FY2024 | 2024-12-31 | (751.56K) | +35.0% |
| FY2023 | 2023-12-31 | (1.16M) | — |
Net Debt vs competitors
How TTRX compares with its peers on the latest reported figures
- TTRX's Mar 2026 net debt of -$5.21M is the 3rd highest of the 9 companies compared; the peer median is -$17.4M.
- Net debt amounts to 28.0% of total assets for TTRX, versus a peer median of 39.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $269.47M | +266.3% | — | 144.5% | |
| Apr 2026 | -$1.29M | +23.4% | — | 8.7% | |
TTRXTurn Therapeutics Inc. | Mar 2026 | -$5.21M | — | — | 28.0% |
| Mar 2026 | -$5.84M | +3.5% | — | 19.7% | |
| Mar 2026 | -$10.51M | -282.0% | — | 100.0% | |
| Mar 2026 | -$24.29M | +10.2% | — | 8.9% | |
| Mar 2026 | -$30.67M | -94.2% | — | 84.9% | |
IRDOpus Genetics, Inc. | Mar 2026 | -$34.03M | +18.6% | — | 50.9% |
| Mar 2026 | -$49.57M | +32.4% | — | 28.6% | |
| Peer median (excluding TTRX) | -$17.4M | +14.4% | — | 39.8% | |
Competitors are the stored peer set for TTRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Turn Therapeutics Inc.
NASDAQ:TTRX
Intrinsic Alpha fair value
Locked
Current Price
$8.89
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.